Ptc Therapeutics, Inc. (PTCT) Institutional Ownership

Ownership Summary

Ptc Therapeutics, Inc. (NASDAQ:PTCT) currently has 292 active institutional owners and shareholders as of today (September 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).

• Institutional ownership in Ptc Therapeutics edged up to 104.5% in September 2025, compared to 99.7% in June 2025.
• The company experienced a 1.78% quarterly change in institutional shares held, alongside an increase of 46.00% in total owners annually.
• Among the 292 institutional holders of Ptc Therapeutics, 148 added to their stakes while 113 trimmed their positions and 31 held steady.
• The aggregate institutional position in Ptc Therapeutics now stands at 83.01Mn shares as of September 2025, after investors increased their holdings (up by 1.45Mn shares quarter on quarter which is up 5.05Mn shares year over year).
• VANGUARD GROUP INC continues to be the largest institutional holder of Ptc Therapeutics as of September 30, 2025, with a position of 8.29Mn shares, representing 10.43% of the company's outstanding stock.
• Among the most significant buyers of Ptc Therapeutics during September 2025 were Jefferies Financial Group Inc. (1.06Mn), TORONTO DOMINION BANK (800.57K), MILLENNIUM MANAGEMENT LLC (672.08K), JANUS HENDERSON GROUP PLC (598.54K), CITADEL ADVISORS LLC (563.40K).
• Leading sellers of Ptc Therapeutics stock in September 2025 included ARMISTICE CAPITAL, LLC (1.46Mn), MORGAN STANLEY (743.92K), VANGUARD GROUP INC (558.47K), Assenagon Asset Management S.A. (523.97K), Man Group plc (406.33K).
• The top 10 institutional holders of Ptc Therapeutics for the quarter ending September 2025 included VANGUARD GROUP INC (8.29Mn), RTW INVESTMENTS, LP (7.75Mn), BlackRock, Inc. (7.13Mn), WELLINGTON MANAGEMENT GROUP LLP (4.92Mn), JANUS HENDERSON GROUP PLC (3.77Mn), ARMISTICE CAPITAL, LLC (3.28Mn), TORONTO DOMINION BANK (3.25Mn), STATE STREET CORP (3.13Mn), D. E. Shaw & Co., Inc. (2.17Mn), GEODE CAPITAL MANAGEMENT, LLC (1.95Mn).